https://www.gyldenpharma.com/emergex-vaccines-provides-an-update-on-agreement-with-midatech-pharma/2020-01-17T11:25:00+00:00https://www.gyldenpharma.com/emergex-vaccines-awarded-sbri-contract-by-innovate-uk/2020-01-17T11:24:36+00:00https://www.gyldenpharma.com/emergex-vaccines-approved-as-member-of-the-social-stock-exchange/2020-01-17T11:23:36+00:00https://www.gyldenpharma.com/emergex-progresses-its-synthetic-vaccine-development-pipeline/2019-02-27T10:21:20+00:00https://www.gyldenpharma.com/emergex-builds-its-finance-team-with-two-new-recruits/2019-02-27T10:21:05+00:00https://www.gyldenpharma.com/sir-david-king-joins-emergexs-board-of-directors/2019-02-27T10:20:18+00:00https://www.gyldenpharma.com/emergex-awarded-innovate-uk-grant-to-progress-its-universal-and-pandemic-flu-vaccine/2019-02-27T10:20:01+00:00https://www.gyldenpharma.com/emergex-files-a-patent-in-the-usa-for-its-novel-pandemic-flu-vaccine/2020-01-17T11:23:54+00:00https://www.gyldenpharma.com/bioworld-thinking-on-a-global-scale-emergex-vaccines-using-lessons-from-ebola-outbreak/2018-06-07T16:05:50+01:00https://www.gyldenpharma.com/emergex-appoints-us-federal-government-experts-the-conafay-group/2019-02-27T10:19:38+00:00https://www.gyldenpharma.com/emergex-enters-into-mou-with-brazils-fiocruz-to-develop-novel-vaccines-against-viral-diseases/2019-02-27T10:19:11+00:00https://www.gyldenpharma.com/emergex-demonstrates-excellent-safety-profile-for-gold-nanoparticle-used-in-its-vaccine-platform/2019-02-27T10:18:52+00:00https://www.gyldenpharma.com/emergex-secures-state-of-the-art-rd-facility-and-hires-a-chief-scientific-officer-to-drive-development-of-its-vaccines/2019-02-27T10:18:33+00:00https://www.gyldenpharma.com/dr-athanasios-papadopoulos-joins-emergex-as-chief-medical-officer/2020-01-17T11:23:09+00:00https://www.gyldenpharma.com/emergex-signs-an-rd-agreement-with-imcb-to-develop-a-vaccine-for-the-emerging-threat-of-hand-foot-mouth-disease/2019-12-10T09:42:15+00:00https://www.gyldenpharma.com/emergex-successfully-completes-preclinical-testing-of-its-lead-set-point-vaccine-candidate-for-dengue-fever-and-other-flaviviruses/2019-12-13T10:40:08+00:00https://www.gyldenpharma.com/emergex-completes-first-step-in-the-development-of-a-vaccine-candidate-against-intracellular-bacterium-and-bioterrorist-agent-francisella-tularensis/2019-12-13T18:02:26+00:00https://www.gyldenpharma.com/emergex-raises-more-than-us11-million-in-a-series-a-round-to-progress-its-pipeline-of-set-point-vaccines-for-infectious-diseases/2020-01-17T11:22:20+00:00https://www.gyldenpharma.com/publication-of-coronavirus-white-papers/2020-04-22T16:54:19+01:00https://www.gyldenpharma.com/emergex-signs-agreement-with-george-mason-university-for-highly-pathogenic-rna-virus-studies/2020-04-22T12:55:51+01:00https://www.gyldenpharma.com/emergex-and-bio-manguinhos-fiocruz-elucidate-t-cell-epitopes-produced-by-commercial-yellow-fever-vaccine/2020-08-19T12:48:37+01:00https://www.gyldenpharma.com/emergex-vaccines-forms-us-subsidiary-emergex-usa-by-acquisition-of-laboratories-technology-and-assets-of-us-based-t-cell-specialist-biotech-immpronano/2020-08-28T17:24:59+01:00https://www.gyldenpharma.com/emergex-vaccines-and-george-mason-university-identify-t-cell-epitopes-presented-by-sars-cov-2-infected-cells/2020-09-15T09:26:04+01:00https://www.gyldenpharma.com/emergex-vaccines-raises-us11-million-to-advance-pipeline-of-synthetic-t-cell-vaccines-for-infectious-diseases/2020-11-18T14:12:09+00:00https://www.gyldenpharma.com/emergex-vaccines-signs-collaboration-agreement-with-brazils-bio-manguinhos-fiocruz-for-the-development-of-a-covid-19-vaccine/2021-01-27T17:25:34+00:00https://www.gyldenpharma.com/emergex-notes-u-s-government-reports-highlighting-the-importance-of-t-cell-immunity-in-controlling-viral-infections/2021-01-28T06:53:14+00:00https://www.gyldenpharma.com/emergex-strengthens-senior-management-team/2021-02-22T16:32:24+00:00https://www.gyldenpharma.com/emergex-appoints-dr-anthony-sedgwick-as-non-executive-director/2021-06-17T07:42:29+01:00https://www.gyldenpharma.com/emergex-receives-regulatory-approval-for-a-phase-i-clinical-trial-in-dengue-of-a-t-cell-priming-vaccine/2021-06-29T22:09:33+01:00https://www.gyldenpharma.com/t-cell-priming-vaccines-offer-the-potential-to-provide-faster-broader-and-longer-lasting-immunity-to-reduce-serious-illness-associated-with-infectious-diseases-such-as-covid-19-heres-why/2021-12-06T10:01:46+00:00https://www.gyldenpharma.com/can-one-vaccine-provide-immune-protection-against-multiple-pathogens/2021-12-06T10:02:36+00:00https://www.gyldenpharma.com/next-generation-covid-19-vaccines-looking-beyond-spike-protein-and-sars-cov-1-variants/2021-12-06T10:02:50+00:00https://www.gyldenpharma.com/emergex-announces-approval-to-initiate-phase-i-clinical-trial-of-its-next-generation-covid-19-vaccine-candidate/2021-12-03T14:55:43+00:00https://www.gyldenpharma.com/nature-paper-provides-further-evidence-of-the-benefits-of-eliciting-a-t-cell-response-for-covid-19/2021-11-11T16:27:50+00:00https://www.gyldenpharma.com/emergex-confirms-its-next-generation-t-cell-priming-covid-19-vaccine-candidate-has-the-potential-to-be-effective-against-all-currently-sequenced-viral-mutations/2021-12-03T13:59:10+00:00https://www.gyldenpharma.com/emergex-awarded-490525-uk-aid-grant-by-the-department-of-health-and-social-care-to-advance-synthetic-t-cell-vaccine-candidate-for-chikungunya-virus/2022-02-22T08:27:28+00:00https://www.gyldenpharma.com/emergex-signs-agreement-with-atcc-to-advance-studies-of-its-yellow-fever-booster-vaccine-candidate/2022-04-06T16:44:22+01:00https://www.gyldenpharma.com/emergex-advances-vaccine-candidate-for-tularemia-highlighting-the-potential-of-t-cell-priming-vaccines-in-national-preparedness-initiatives/2022-04-22T10:59:22+01:00https://www.gyldenpharma.com/emergex-provides-an-update-on-first-in-human-studies-of-its-novel-dengue-fever-and-coronavirus-t-cell-adaptive-vaccines/2022-04-14T16:07:58+01:00https://www.gyldenpharma.com/emergex-vaccines-announces-the-successful-coating-of-its-novel-cd8-t-cell-adaptive-covid-19-vaccine-onto-zosano-pharmas-micro-needle-patch/2022-05-17T13:12:39+01:00https://www.gyldenpharma.com/emergex-vaccines-signs-heads-of-terms-for-a-collaboration-with-molecular-biology-institute-of-parana-ibmp-in-brazil/2022-06-30T16:22:37+01:00https://www.gyldenpharma.com/emergex-announces-gmp-production-of-its-cd8-t-cell-universal-influenza-vaccine/2022-07-28T07:58:39+01:00https://www.gyldenpharma.com/emergex-acquires-intradermal-and-patch-drug-delivery-technology-with-its-manufacturing-equipment-from-zosano-pharma/2022-10-11T17:19:39+01:00https://www.gyldenpharma.com/emergex-confirms-synthesis-of-a-cd8-t-cell-adaptive-vaccine-for-smallpox-and-monkeypox/2022-10-18T10:08:22+01:00https://www.gyldenpharma.com/emergex-generates-chikungunya-ligandome-a-milestone-in-the-development-of-its-t-cell-adaptive-vaccine/2022-11-28T15:59:45+00:00https://www.gyldenpharma.com/emergex-announces-positive-phase-i-trial-data-for-denguetcp-its-novel-t-cell-priming-immune-set-point-candidate/2023-07-21T16:34:33+01:00https://www.gyldenpharma.com/emergex-and-brazils-ibmp-announce-clinical-development-collaboration-for-t-cell-priming-immune-set-point-candidates/2023-06-21T13:32:56+01:00https://www.gyldenpharma.com/emergex-appoints-sir-michael-rake-as-board-chairman/2023-06-29T14:30:04+01:00https://www.gyldenpharma.com/emergex-reports-promising-data-from-completed-swiss-phase-i-trial-of-coronatcp-t-cell-priming-immune-set-point-candidate-for-betacoronaviruses/2024-07-16T11:32:11+01:00https://www.gyldenpharma.com/emergex-and-saudi-arabias-vaccine-industrial-company-vic-have-signed-mou-to-advance-first-of-its-kind-infectious-disease-solutions/2023-10-05T14:04:58+01:00https://www.gyldenpharma.com/emergex-signs-contract-of-179m-with-the-uk-department-of-health-and-social-cares-uk-vaccine-network-ukvn-to-advance-its-novel-synthetic-t-cell-priming-set-point-candidate/2023-11-17T16:48:28+00:00https://www.gyldenpharma.com/successful-transfer-of-new-drug-application-nda-acknowledged-by-u-s-fda-from-former-zosano-pharma-to-emergex-for-investigational-microneedle-based-drug-delivery-patch/2023-12-18T12:48:29+00:00https://www.gyldenpharma.com/emergex-announces-authorisation-from-philippines-fda-to-initiate-phase-i-ii-clinical-trial-of-coronatcp/2024-01-03T16:55:18+00:00https://www.gyldenpharma.com/emergex-announces-rd-collaboration-with-deka-research-development-corp-for-assessment-of-emergexs-immunotherapeutic-candidates-with-dekas-intradermal-therapeutic-applicator/2024-01-15T16:41:44+00:00https://www.gyldenpharma.com/emergex-announces-mhra-approval-of-mia-imp-manufacturing-and-import-authorisation-license/2024-06-18T11:55:40+01:00https://www.gyldenpharma.com/emergex-receives-patent-protection-for-first-in-class-influenza-a-vaccines-with-potential-to-provide-long-term-t-cell-immunity/2024-08-22T16:35:50+01:00https://www.gyldenpharma.com/emergex-t-cell-priming-vaccine-candidate-for-betacoronaviruses-selected-by-nih-niaid-project-nextgen-for-inclusion-in-clinical-trials/2024-10-02T14:40:08+01:00https://www.gyldenpharma.com/emergex-announces-company-name-change-to-gylden-pharma-limited-reflecting-companys-commitment-to-advanced-core-technologies-and-expanded-product-pipeline/2024-10-18T09:31:36+01:00https://www.gyldenpharma.com/gyldens-2025-strategic-priorities-for-advancing-innovative-and-transformative-solutions-for-infectious-diseases/2025-02-24T12:54:27+00:00